Ben has 15 years’ experience as an Entrepreneur, Scientist and Biotech Investor. He founded Aerovate to develop therapies with the potential to meaningfully change the treatment of rare diseases. Informed by his training in diseases of aberrant proliferation, he views PAH drug development through a unique lens focusing Aerovate on anti-proliferative therapies that directly address the root cause of disease.

Donna has more than two decades of regulatory experience in the pharmaceutical industry, with deep expertise in designing and implementing regulatory strategies for delivering new medicines to patients. Prior to operating a regulatory affairs consultancy, Donna spent 35 years with AstraZeneca, where she led the development and implementation of global regulatory strategies supporting the approval of new treatments for asthma, COPD, rhinitis, and atrial fibrillation, as well as for new device platforms, and was responsible for interactions with health authorities related to NDA/MAA submissions.

George has 25 years of experience in biotech, serving as CFO for several biotechnology companies including Curis, Targanta and Proteon. George’s extensive background in raising capital includes private, IPO and follow-on settings, investment banking and M&A.

Sue has more than 20 years of experience in clinical operations in both academic and pharmaceutical industry settings. She previously built and led high functioning clinical operations teams at EMD Serono, Acetylon Pharmaceuticals and Syndax Pharmaceuticals. Prior to that, Sue spent six years supporting clinical research at Massachusetts General Hospital and Dana-Farber/Harvard Cancer Center.  Sue’s expertise includes delivery of clinical trials across all phases of development in multiple therapeutic areas, team and people development, large scale vendor oversight, contracting and management, GCP and inspection readiness.

Hunter has been developing treatments for patients with pulmonary hypertension for more than two decades. He has designed and executed Phase 2 and Phase 3 programs for cardiopulmonary diseases resulting in the approval of multiple drugs for pulmonary arterial hypertension. His work helped establish the current dual combination therapy used as the frontline standard of care in PAH.

Sanjeev Khindri joined our leadership team as Executive Vice President, Clinical Development. Dr. Khindri has more than 15 years of experience as a clinical trialist and leader across all stages of clinical development in respiratory medicine including experience in rare diseases such as PAH and Idiopathic Pulmonary Fibrosis as well as a strong understanding of pediatric drug development and orphan drug legislation. He previously led medical teams at Akari Pharmaceuticals plc, Actelion Ltd., Galecto Biotech AB, and GSK plc. He trained in adult internal medicine and clinical pharmacology in the United Kingdom.

Cheryl joins Aerovate as Senior Vice President Clinical Development, bringing a wealth of clinical development (phase 1-3) experience, particularly in pulmonary hypertension and respiratory diseases. She joins Aerovate from Janssen where she held clinical leadership positions with responsibility for a selexipag, macitentan 10mg, macitentan 75mg and the fixed dose combination (macitentan/tadalafil). She was instrumental in leading the clinical submission team for the recent NDA and EMA regulatory filings of the first FDC in PAH. Cheryl has worked at companies such as ARENA which included their oral prostacyclin (ralinepag), Cytos, Epirus, Novartis, BMS, Abbott and Pharmacia in a wide array of indications. Cheryl holds a Medical degree and a Science degree.

Ralph has over 25 years of broad experience in translational medicine with a specific emphasis on inhaled drug development. Ralph has driven the experimental and clinical development of small molecules and biomolecules employing a variety of delivery systems, at both startups and large pharmaceutical companies including Novartis, APT Pharmaceuticals, and Amgen.

Tim has 30 years’ industry experience leading all aspects of R&D and commercialization in the biopharmaceutical industry including Merck, Genzyme and Proteon. His extensive commercial planning and launch experience while at Genzyme, included leading the planning and commercialization of Renagel, a treatment for hemodialysis patients that resulted in Genzyme’s acquisition of GelTex for more than $1 billion.

Tim has over 25 years of industry experience in launching and commercializing a range of products over multiple therapeutic areas. These include leading the launches of multiple products in rare cardiopulmonary diseases such as Revatio and Letairis in pulmonary arterial hypertension, Cayston in cystic fibrosis, and preparing for the launch of mavacamten in obstructive hypertrophic cardio-myopathy.

Marco has over 15 years of product development and manufacturing experience. He has worked on multiple commercial products, leading them from clinical product development through NDA filing and commercial launch. He joins Aerovate from Vertex, where he helped develop Kalydeco and Orkambi, Flexion Therapeutics, where he helped develop and launch Zilretta, and most recently Epizyme, where he helped develop and launch Tazverik.

Stephen has more than 20 years of global regulatory compliance and quality management systems experience in the pharmaceutical and life science industry from early phase development to commercial operations. He previously led Quality teams at Allena Pharmaceuticals Inc., Lyndra Therapeutics, Inc., and Immunogen, Inc.